SCHEDULE: Fairmount Funds Files Schedule 13D for Jade Biosciences

Fairmount Funds Management LLC reports a 19.99% beneficial ownership stake in Jade Biosciences following a lock-up agreement.

Summary

• Fairmount Funds Management LLC and its affiliates maintain a 19.99% beneficial ownership stake in Jade Biosciences, Inc.
• The reporting persons entered into a 60-day lock-up agreement with underwriters Jefferies LLC, TD Securities, and UBS Securities in connection with a June 2026 public offering.
• The filing confirms that the number of shares held by the reporting persons remains unchanged since the previous amendment.
• Director Tomas Kiselak had 23,017 stock options vest on April 29, 2026, at an exercise price of $10.14 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing; it confirms existing institutional support but does not signal a change in investment strategy or new capital deployment.

Positives

• The reporting group maintains a significant 19.99% stake, signaling continued institutional commitment to the issuer.
• The lock-up agreement provides short-term stability for the company's share price following the recent public offering.

Negatives

• The reporting persons did not participate in the recent public offering, which may be viewed as a lack of incremental investment.

Risks

• Beneficial ownership is subject to strict limitations (9.99% for warrants and 19.99% for preferred stock) which restrict the ability of the reporting persons to exercise or convert holdings.
• The lock-up agreement restricts the liquidity of the reporting persons' shares for 60 days.

Future Outlook

The reporting persons are subject to a 60-day lock-up period ending in early August 2026, during which they cannot sell shares without underwriter consent.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory update for institutional investors in the biotech sector, reflecting participation in the capital structure of a company undergoing a public offering.

Comparison to Industry Standards

• The use of 19.99% ownership caps is a standard practice for institutional investors to avoid triggering certain regulatory thresholds or 'control person' status under SEC rules.
• The 60-day lock-up period is consistent with standard market practice for underwriters following a public offering.

Corporate Governance

Stakeholder Impact

• Shareholders: The lock-up agreement provides temporary stability by preventing large-block sales by major investors.
• Creditors: No direct impact.

Next Steps

• Expiration of the 60-day lock-up agreement in August 2026.

Key Dates

Keywords

Jade Biosciences, Fairmount Funds, Schedule 13D, Lock-up Agreement, Institutional Ownership, Biotech